Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1714/3689.36748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: From multimodality imaging to catheter ablation of ventricular arrhythmias in arrhythmogenic mitral valve prolapse.
Front Physiol
August 2025
Department of Electrophysiology, King Abdulaziz Cardiac Center, King Abdullah International Medical Research Center (KAIMRC), MNGHA, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Background: Mitral valve prolapse (MVP) is a common condition, typically benign, but in a small subset of patients, it may lead to life-threatening arrhythmias and sudden cardiac death (SCD). This arrhythmogenic MVP phenotype is often associated with bileaflet prolapse, mitral annular disjunction (MAD), and myocardial fibrosis identified via late gadolinium enhancement (LGE) on cardiac MRI.
Case Summary: Our patient is a 49-year-old man presented with monomorphic ventricular tachycardia and near-syncope.
The Natural History and Clinical Outcomes of Transmembrane Protein 43 Cardiomyopathy: A Systematic Review.
J Clin Med
August 2025
Department of Cardiac, Thoracic, and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy.
Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disorder characterized by structural and functional myocardial alterations, often accompanied by ventricular arrhythmias (VAs), which may ultimately result in sudden cardiac death (SCD). While mutations in genes coding for desmosomal components are commonly identified in affected individuals, genetic variants involving non-desmosomal proteins have recently been recognized as contributors to the disease's etiology. In 2008, a mutation in the transmembrane protein 43 () was identified as being responsible for a fully penetrant, sex-related, and severe form of ACM.
View Article and Find Full Text PDFReducing Unnecessary Implantable Cardioverter-Defibrillator Therapy With ENHANCED Programming: Long-Term Outcomes of the ENHANCED-ICD Study.
J Cardiovasc Electrophysiol
August 2025
Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, the Netherlands.
Background: Advances in implantable cardioverter-defibrillator (ICD) programming strategies have achieved significant reductions in inappropriate shocks. However, further refinement is needed to minimize appropriate but unnecessary therapies. The ENHANCED-ICD study initially demonstrated the short-term safety and efficacy of programming a number of intervals to detect (NID) of 60/80 over a median follow-up of 1.
View Article and Find Full Text PDFPathogenic KCNH2 variant in monozygotic twins with speech delay and lower risk type 2 long QT syndrome.
Neurogenetics
August 2025
Human Genetics Lab, Altamedica Main Centre, Viale Liegi 45, Rome, 00198, Italy.
Type 2 Long QT Syndrome (type 2 LQTS) is a cardiac channelopathy caused by pathogenic variants in the KCNH2 gene, often associated with delayed cardiac repolarization and increased risk of arrhythmias. While its impact is traditionally considered cardiac, emerging studies suggest a potential role of KCNH2 dysfunction in neurogical disorders. We describe monozygotic twin sisters carrying the pathogenic frameshift variant KCNH2 c.
View Article and Find Full Text PDFIncessant Electrical Storm in a Patient With Brugada Syndrome Provoked by Previously Unreported Syndrome-Inducing Medication.
JACC Case Rep
August 2025
First Coast Cardiovascular Institute, Jacksonville, Florida, USA.
Background: Brugada syndrome is a disorder associated with an increased risk of syncope, ventricular fibrillation, and sudden cardiac death in a structurally normal heart. The condition is related to mutations in cardiac cell transmembrane channels, but many cases do not have identifiable genetic mutations. Arrhythmic events are usually induced by specific triggers including a number of medications.
View Article and Find Full Text PDF